About IntelliPharmaCeutics Intl (NASDAQ:IPCI)
Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IPCI
CUSIPN/A
Phone416-798-3001
Debt
Debt-to-Equity RatioN/A
Current Ratio0.29%
Quick Ratio0.25%
Price-To-Earnings
Trailing P/E Ratio-1.31
Forward P/E Ratio-3.80
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.51 million
Price / Sales3.00
Cash FlowN/A
Price / CashN/A
Book Value($0.06) per share
Price / Book-6.33
Profitability
EPS (Most Recent Fiscal Year)($0.29)
Net Income$-8,850,000.00
Net Margins-217.52%
Return on Equity-2,811.75%
Return on Assets-147.15%
Miscellaneous
Employees54
Outstanding Shares43,540,000
IntelliPharmaCeutics Intl (NASDAQ:IPCI) Frequently Asked Questions
What is IntelliPharmaCeutics Intl's stock symbol?
IntelliPharmaCeutics Intl trades on the NASDAQ under the ticker symbol "IPCI."
How were IntelliPharmaCeutics Intl's earnings last quarter?
IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) released its quarterly earnings results on Friday, February, 16th. The company reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by $0.01. The firm had revenue of $1.08 million for the quarter, compared to analyst estimates of $1.32 million. IntelliPharmaCeutics Intl had a negative return on equity of 2,811.75% and a negative net margin of 217.52%. View IntelliPharmaCeutics Intl's Earnings History.
When is IntelliPharmaCeutics Intl's next earnings date?
What price target have analysts set for IPCI?
3 brokerages have issued 1 year target prices for IntelliPharmaCeutics Intl's shares. Their forecasts range from $2.00 to $3.10. On average, they expect IntelliPharmaCeutics Intl's share price to reach $2.70 in the next year. View Analyst Ratings for IntelliPharmaCeutics Intl.
What are Wall Street analysts saying about IntelliPharmaCeutics Intl stock?
Here are some recent quotes from research analysts about IntelliPharmaCeutics Intl stock:
- 1. According to Zacks Investment Research, "Intellipharmaceutics International Inc. is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Its products include Effexor XR and Protonix. The Company offers products in different stages of development in therapeutic areas, including neurology, cardiovascular, and GIT. Intellipharmaceutics International Inc. was formerly known as IntelliPharmaCeutics Ltd. and is based in Toronto, Canada. " (4/25/2018)
- 2. Maxim Group analysts commented, "1Q18 revenues were $0.3M, down from $1.1M in 4Q17 (Nov. YE). The decline owes largely to declining generic Focalin sales, citing pricing pressures in the US generics market. IPCI recently raised $4.5M through an equity financing, which extends the runway into 3Q18. However, we believe that over time the generics business for IPCI will continue to grow and provide revenue that helps offset cash burn associated with key programs: Abuse deterrent Oxycodone and PODRAS (preventing overdose); we view both programs as the long-term drivers of the company." (4/18/2018)
Who are some of IntelliPharmaCeutics Intl's key competitors?
Some companies that are related to IntelliPharmaCeutics Intl include Oncolytics Biotech (ONCYF), Elite Pharmaceuticals (ELTP), Northwest Biotherapeutics (NWBO), Oasmia Pharmaceutical (OASM), SteadyMed (STDY), Neurotrope (NTRP), Xenon Pharmaceuticals (XENE), Axsome Therapeutics (AXSM), Helix Biopharma (HBPCF), Regulus Therapeutics (RGLS), Vascular Biogenics (VBLT), Genprex (GNPX), Sophiris Bio (SPHS), vTv Therapeutics (VTVT) and Acerus Pharmaceuti (TRLPF).
Who are IntelliPharmaCeutics Intl's key executives?
IntelliPharmaCeutics Intl's management team includes the folowing people:
- Isa Odidi Ph.D., Chairman of the Board, Chief Executive Officer
- Amina Odidi Ph.D., President, Chief Operating Officer, Director
- Andrew Patient, Chief Financial Officer
- John N. Allport, Vice President - Legal Affairs and Licensing, Secretary, Director
- Patrick N. Yat Ph.D., Vice President - Pharmaceutical Analysis and Chemistry
- Kenneth Keirstead, Independent Director
- Bahadur Madhani, Independent Director
- Eldon R. Smith M.D., Independent Director (Age 75)
Has IntelliPharmaCeutics Intl been receiving favorable news coverage?
Press coverage about IPCI stock has trended somewhat positive on Thursday, according to Accern Sentiment. The research firm scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. IntelliPharmaCeutics Intl earned a media sentiment score of 0.10 on Accern's scale. They also assigned media headlines about the company an impact score of 46.64 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are IntelliPharmaCeutics Intl's major shareholders?
How do I buy shares of IntelliPharmaCeutics Intl?
Shares of IPCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IntelliPharmaCeutics Intl's stock price today?
One share of IPCI stock can currently be purchased for approximately $0.38.
How big of a company is IntelliPharmaCeutics Intl?
IntelliPharmaCeutics Intl has a market capitalization of $18.72 million and generates $5.51 million in revenue each year. The company earns $-8,850,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. IntelliPharmaCeutics Intl employs 54 workers across the globe.
How can I contact IntelliPharmaCeutics Intl?
IntelliPharmaCeutics Intl's mailing address is 30 WORCESTER ROAD, TORONTO A6, M9W 5X2. The company can be reached via phone at 416-798-3001 or via email at [email protected]
MarketBeat Community Rating for IntelliPharmaCeutics Intl (IPCI)
MarketBeat's community ratings are surveys of what our community members think about IntelliPharmaCeutics Intl and other stocks. Vote "Outperform" if you believe IPCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPCI will underperform the S&P 500 over the long term. You may vote once every thirty days.
IntelliPharmaCeutics Intl (NASDAQ:IPCI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for IntelliPharmaCeutics Intl in the last 12 months. Their average twelve-month price target is $2.70, suggesting that the stock has a possible upside of 610.53%. The high price target for IPCI is $3.10 and the low price target for IPCI is $2.00. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Buy | Hold |
| Consensus Rating Score: | 2.33 | 2.25 | 2.50 | 2.33 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $2.70 | $2.5250 | $2.40 | $2.3667 |
| Price Target Upside: | 610.53% upside | 300.79% upside | 200.00% upside | 134.32% upside |
IntelliPharmaCeutics Intl (NASDAQ:IPCI) Consensus Price Target History
IntelliPharmaCeutics Intl (NASDAQ:IPCI) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
IntelliPharmaCeutics Intl (NASDAQ:IPCI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
IntelliPharmaCeutics Intl (NASDAQ IPCI) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 9.02%
IntelliPharmaCeutics Intl (NASDAQ IPCI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
IntelliPharmaCeutics Intl (NASDAQ IPCI) News Headlines
| Source: |
|
IntelliPharmaCeutics Intl (NASDAQ:IPCI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
IntelliPharmaCeutics Intl (NASDAQ:IPCI) Income Statement, Balance Sheet and Cash Flow Statement
IntelliPharmaCeutics Intl (NASDAQ IPCI) Stock Chart for Thursday, April, 26, 2018
Loading chart…
